History

Jan.

PharmAbcine announces a research collaboration with LegoChem Biosciences

Dec.

PharmAbcine to present the final data of Phase IIa rGBM trial at SNO 2020


Certification of Excellent Corporation R&D Center(ECRC)



Nov.

PharmAbcine to present the final data of Phase IIa rGBM trial at SNO 2020



Sep.

PharmAbcine Unveils Olinvacimab's Positive Results from Phase Ib Combination Studies at KSMO 2020


PMC-403 and PMC-309 wins Poster Award at Korean Society of Medical Oncology(KSMO) 2020



Aug.

PharmAbcine announces the execution of a Material Cooperative Research and Development Agreement (MCRADA) with the NIH to evaluate the efficacy of PMC-403 to treat SCLS


PharmAbcine expands partnership with Samsung Biologics for PMC-403



PharmAbcine signs a research collaboration agreement with Wuxi Shuangliang Biotechnology(SLBio) to evaluate a combination therapy to treat NSCLC



Jun.

PharmAbcine Signs Long-term Contract Manufacturing Organization Agreement for Olinvacimab with Binex


PharmAbcine enters into a development and manufacturing partnership with Thermo Fisher for PMC-309



Apr.

PharmAbcine signs a license agreement with Wincal Biopharm to expand indications of PharmAbcine's existing assets to non-oncology areas


Samsung Biologics enters into a development and manufacturing partnership with PharmAbcine for oncology and neovascular treatment



Jan.

Company incorporation in the U.S


Nov.

FPFV(First Patient Fist Visit) of phase 2 study of Olinvacimab treatment for rGBM patients who have progressed after bevacizumab treatment



Sep.

FPFV(First Patient Fist Visit) of phase 2 study of Olinvacimab treatment for rGBM patients who have progressed after bevacizumab treatment



Aug.

Approval US IRB(Stanford Hospital) of Olinvacimab phase 2 study for the treatment of rGBM patient who has progressed after bevacizumab treatment


Approval Australia HREC of Olinvacimab phase 2 study for the treatment of rGBM patient who has progressed after bevacizumab treatment



May.

Issuance of CB(KRW 100 Billion)


PharmAbcine enters into a development and manufacturing partnership with Thermo Fisher for PMC-309



Jan.

FPFV(First patient First visit) on the study of Olinvacimab/Pembrolizumab combination trial for the treatment of rGBM patients


FPFV(First patient First visit) on the study of Olinvacimab/Pembrolizumab combination trial for the treatment of mTNBC patients

Dec.

Olinvacimab + Keytruda combo phase 1b/2 for both recurrent Glioblastoma multiforme and metastatic Triple Negative Breast Cancer trials are open to recruit patients at multicenter in Australia



Nov.

November 21, 2018 / KOSDAQ listed


Company incorporation in Australia



Oct.

Orphan drug development appointed



Sep.

Approval of Olinvacimab Phase II IND for Avastine refractory rGBM Patients


Biologics Award



Mar.

ODD approval of Olinvacimab for rGBM



Jan.

Clinical Research Collaboration for Combo Trials



Jun.

Completion of Olinvacimab Phase IIa for rGBM Patients



Apr.

Commendation from KHIDI


Jun.

Commendation from KFDS



Feb.

Start of Olinvacimab Phase IIa for rGBM Patients




Oct.

Olinvacimab Achieved an excellence in national R&D Selected for 100 selections as the best accomplishments Awarded from Ministry of Science and ICT



Sep.

Nominated as Korea Brain Power Company in 2015


Dec.

Out-Licensing PMC-001


Health and Medical Technology Development Business Award(CEO)



Nov.

Award from the Minister from KMTIE

- Distinguished Industrial Engineer(CEO)

- Technology Commercialization(CFO)



Oct.

Out-Licensing of Olinvacimab



Jul.

Out-Licensing of PMC-001



Jun.

Tech-Connect National Innovation Award



May.

Korea Eureka Day Award 2014



Mar.

Out-Licensing of Olinvacimab


Selected as INNOBIZ company


Oct.

Ministry of Education Award



Sep.

Completion of Olinvacimab Phase 1



Mar.

Out-Licensed of 1E4 mAb

Nov.

Research collaboration with Sanofi-Aventis



Apr.

Pharma -Idol Award from 7th Annual China Pharmaceutical R&D Summit Conference


Nov.

Start of Olinvacimab (TTAC-0001, formerly known as tanibirumab) Phase 1



Sep.

Green Technology Citification



Jul.

Olinvacimab IND approved

Dec.

R&D Center affiliated



Sep.

Designation of foreign investment company



Mar.

Certificated as venture business

Oct.

Grand Prix from 1st GATE Project



Sep.

September 9, 2008 / Foundation of PharmAbcine Inc.



LinkedIn  I   Facebook  I  YouTube



    • 2F, Research Building 2, 70, Yuseong-daero 1689 beon-gil,
      Yuseong-gu, Daejeon, 34047, Republic of Korea
    • HQ +82-42-863-2017
    • R&D Center +82-42-861-2017
    • FAX +82-42-863-2080
  • COPYRIGHT BY PharmAbcine Inc. ALL RIGHTS RESERVED.